A Performance Evaluation of Commercial Fibrinogen Reference Preparations and Assays for Clauss and PT-derived Fibrinogen

Summary

The wide availability of fibrinogen estimations based on the prothrombin time (PT-Fg) has caused concern about the variability and clinical utility of fibrinogen assays. In a multi-centre study, we investigated fibrinogen assays using various reagents and analysers. Clauss assays generally gave good agreement, although one reagent gave 15–30% higher values in DIC and thrombolysis. Two commercial reference preparations had much lower potencies than the manufacturers declared, and plasma turbidity influenced parallelism in some Clauss assays. PT-Fg assays gave higher values than Clauss and showed calibrant dependent effects, the degree of disparity correlating with calibrant and test sample turbidity. Analyser and thromboplastin dependent differences were noted. The relationship between Clauss and PT-Fg assays was sigmoid, and the plateau of maximal PT-Fg differed by about 2 g/l between reagents. ELISA and immunonephelometric assays correlated well, but with a high degree of scatter. Antigen levels were higher than Clauss, but slightly lower than PT-Fg assays, which appeared to be influenced by degraded fibrinogen. Clauss assays are generally reproducible between centres, analysers and reagents, but PT-Fg assays are not reliable in clinical settings.

Keywords

Fibrinogen assays - coagulation analysers - Clauss reagents - thromboplastin reagent - reference plasmas

• References

• 1 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
• 2 Chantarangkul V, Tripodi A, Mannucci PM. Results of a collaborative study for fibrinogen measurement. Evidence that the use of a common calibrator improves interlaboratory agreement. Blood Coagul Fibrinolysis 1994; 05: 761-6.
• 3 Gaffney PJ, Wong MY. Collaborative study of a proposed International Standard for plasma fibrinogen measurement. Thromb Haemost 1992; 68: 428-32.
• 4 U.K. National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Report on Survey 120. August 2000
• 5 Palareti G, Maccaferri M, Manotti C, Tripodi A, Chantarangkul V, Rodeghiero F, Ruggeri M, Mannucci PM. Fibrinogen assays: A collaborative study of six different methods. C.I.S.M.E.L Comitaro Italiano per la Standardizzione dei Methodi in Ematologia e Labatorio 1991; 37: 714-9.
• 6 Chitolie A, Mackie IJ, Grant D, Hamilton JL, Machin SJ. Inaccuracy of the ‘derive’ fibrinogen measurement. Blood Coagul Fibrinolysis 1994; 05: 955-7.
• 7 Chitolie A, Mackie IJ, Machin SJ. The type of thromboplastin reagent has important effects on the PT-derived fibrinogen potency. Laboratory Hematology 1998; 04: 149-55.
• 8 Lawrie AS, McDonald SJ, Purdy G, Mackie IJ, Machin SJ. Prothrombin time derived fibrinogen determination on the Sysmex CA-6000™. J Clin Pathol 1998; 51: 462-6.
• 9 Rossi E, Mondonico P, Lombardi A, Preda L. Method for determination of functional (clottable) fibrinogen by the new family of ACL coagulometers. Thromb Res 1988; 52: 453-68.
• 10 de Cristofaro R, Landolfi R. Measurement of plasma fibrinogen concentration by the prothrombin-time-derived method: applicability and limitations. Blood Coagul Fibrinolysis 1998; 09: 251-9.
• 11 Medical Devices Agency Evaluation Report: Fibrinogen Standards and Reference preparations. MDA/99/47, Her Majesty’s Stationery Office; Norwich, UK: 1999
• 12 Medical Devices Agency Evaluation Report: Fibrinogen Assay Reagents and Methods. MDA/2000/01, Her Majesty’s Stationery Office; Norwich, UK: 2000
• 13 Kitchen S, Malia RG, Preston FE. A comparison of methods for the measurement of activated factor VII. Thromb Haemost 1992; 68: 301-5.
• 14 Chanarin I. Laboratory Haematology. An account of laboratory techniques. Churchill Livingstone; Edinburgh: 1989: 279-80.
• 15 Jacobsson K. Studies in the determination of fibrinogen in human blood plasma. Scan J Clin Lab Invest 1955; 07 (Suppl. 14) 1-54.
• 16 Finney DJ. Statistical methods in Biological Assays. Third Edition. Charles Griffin and Company Ltd; 1978
• 17 Rampling MW, Gaffney PJ. Measurement of fibrinogen in plasma. In: Prog Chemical Fibrinolysis and Thrombosis. Davidson JF, Samama MM, Desnoyers PC. eds. Raven Press; New York: 1976. Vol. 2, 91-105.
• 18 de Maat MPM, Lowe GDO, Haverkate F. Fibrinogen. In: Laboratory Techniques in Thrombosis – A Manual. Jespersen J, Bertina RM, Haverkate F. eds. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1999: 79-88.
• 19 Vermylen C, de Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 1963; 08: 418-24.
• 20 Natelson EA, Dooley DF. Rapid determination of fibrinogen by thrombokinetics. Am J Clin Pathol 1974; 61: 828-33.
• 21 Becker U, Bartl K, Wahlefeld AW. A functional photometric assay for plasma fibrinogen. Thromb Res 1984; 35: 475-84.
• 22 Chantarangkul V, Tripodi A, Mannucci PM. Evaluation of a fully automated centrifugal analyzer for performance of hemostasis tests. Clin Chem 1987; 33: 1888-90.
• 23 De Metz M, van Wersch JWJ. Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory. Haemostasis 1987; 17: 254-9.
• 24 Cambas JP, Bierme R, Martinon JC, Dousset B. Evaluation des performances d’un automate en coagulation: l’Electra 700. Nouv Rev Fr Hematol 1985; 25: 313-20.
• 25 Hoffmann JJML, Verhappen MAL. Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. Clin Chem 1988; 34: 2135-40.
• 26 Kitchen S, Jennings I, Preston FE. Comparison of fibrinogen determinations using a Clauss assay and two prothrombin time derived methods. Thromb Haemost 1995; 73: 1245 (A).
• 27 Lowe GDO, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-72.
• 28 Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel C. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
• 29 Sweetnam PM, Yarnell JWG, Lowe GDO, Baker IA, O’Brien JR, Rumley A, Etherington MD, Whitehead PJ, Elwood PC. The relative predictive power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol 1998; 100: 582-8.
• 30 Hantgan RR, Francis CW, Marder VJ. Fibrinogen structure and physiology. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. JB Lippincott Co; Philadelphia: 1994: 277-300.
• 31 Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: The third Glasgow MONICA survey. I) Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84.
• 32 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
• 33 Humphries SE, Henry JA, Montgomery HE. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis 1999; 10 (Suppl. 01) S17-S21.
• 34 Halbmayer WM, Haushofer A, Schon R, Radek J, Fischer M. Comparison of a new automated kinetically determined fibrinogen assay with the 3 most used fibrinogen assays (functional, derived and nephelometric) in Austrian laboratories in several clinical populations and healthy controls. Haemostasis 1995; 25: 114-23.
• 35 Furlan M, Felix R, Escher N, Lammle B. How high is the true fibrinogen content of fibrinogen standards?. Thromb Res 1989; 56: 583-92.
• 36 Whitton CM, Sands D, Hubbard AR, Gaffney PJ. A collaborative study to establish the 2nd international standard for fibrinogen, plasma. Thromb Haemost 2000; 84: 258-62.
• 37 Nieuwenhuizen W, Bos R. Soluble fibrin and degradation products of fibrinogen (FgDP), fibrin (FbDP; D-dimer) and total of FgDP and FbDP (TDP). In: Laboratory Techniques in Thrombosis – A Manual. Jespersen J, Bertina RM, Haverkate F. eds. Kluwer Academic Publishers; Dordrecht, The Netherlands: 1999: 275-84.
• 38 Oosting JD, Hoffmann JJML. Evaluation of an automated photometric fibrinogen assay. Blood Coagul Fibrinolysis 1997; 08: 321-6.
• 39 Hoffman M, Greenberg CS. The effects of fibrin polymerization inhibitors on quantitative measurements of plasma fibrinogen. Am J Clin Pathol 1987; 88: 490-3.